ABSTRACT
Surgical management of gastrointestinal stromal tumors: our experience. Gastrointestinal stromal tumors (GIST) are rare neoplasm even if they are the most common mesenchimal malignancies of the gastrointestinal tract. GIST have long been a source of confusion and controversy, in particular to define their pathological classification, preoperative diagnosis, management strategies, and prognosis. A radical resection of the tumor is often possible and always recommended. Recent studies have identified its principal pathogenic defect. An effective adjuvant therapy treatment (STI571) have been found for advanced and metastatic GIST.
Subject(s)
Gastrointestinal Neoplasms/surgery , Sarcoma/surgery , Antineoplastic Agents/therapeutic use , Benzamides , Chemotherapy, Adjuvant , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/surgery , Disease-Free Survival , Enzyme Inhibitors/therapeutic use , Follow-Up Studies , Gastrectomy , Gastrointestinal Neoplasms/drug therapy , Humans , Ileal Neoplasms/drug therapy , Ileal Neoplasms/surgery , Imatinib Mesylate , Jejunal Neoplasms/genetics , Jejunal Neoplasms/surgery , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Retroperitoneal Neoplasms/surgery , Retrospective Studies , Sarcoma/drug therapy , Stomach Neoplasms/drug therapy , Stomach Neoplasms/surgery , Treatment OutcomeABSTRACT
The authors report their experience about a polychemotherapeutical treatment with CDDP in a woman bearer of 4th stage ovarian cancer. They shortly analyse the biologic features and acting mechanism of CDDP, and outline its indications and limits. The thorough regression observed in the case treated is related to the literature data pointing out the validity of this drug and its usefulness in particular neoplasiae and in carefully selected patients.
